EP Wealth Advisors LLC Buys New Position in Biogen Inc (BIIB)

EP Wealth Advisors LLC purchased a new position in Biogen Inc (NASDAQ:BIIB) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 32,521 shares of the biotechnology company’s stock, valued at approximately $10,360,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Girard Partners LTD. grew its position in Biogen by 16.6% in the 3rd quarter. Girard Partners LTD. now owns 1,125 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 160 shares during the last quarter. IFC Holdings Incorporated FL grew its position in Biogen by 4.1% in the 4th quarter. IFC Holdings Incorporated FL now owns 4,050 shares of the biotechnology company’s stock worth $1,293,000 after purchasing an additional 160 shares during the last quarter. Cue Financial Group Inc. grew its position in Biogen by 11.3% in the 4th quarter. Cue Financial Group Inc. now owns 1,628 shares of the biotechnology company’s stock worth $519,000 after purchasing an additional 165 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in Biogen by 77.0% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 174 shares during the last quarter. Finally, Linscomb & Williams Inc. grew its position in Biogen by 13.5% in the 4th quarter. Linscomb & Williams Inc. now owns 1,481 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 176 shares during the last quarter. Institutional investors own 88.93% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other Biogen news, EVP Alfred Sandrock sold 259 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $290.83, for a total value of $75,324.97. Following the completion of the transaction, the executive vice president now directly owns 6,553 shares of the company’s stock, valued at $1,905,808.99. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert W. Pangia sold 5,832 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the transaction, the director now directly owns 23,539 shares of the company’s stock, valued at $7,759,631.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,128 shares of company stock valued at $2,601,512. Insiders own 0.25% of the company’s stock.

Several analysts have recently weighed in on BIIB shares. HC Wainwright reiterated a “buy” rating and set a $363.00 target price (up from $340.00) on shares of Biogen in a research report on Friday, January 26th. BidaskClub lowered shares of Biogen from a “hold” rating to a “sell” rating in a research report on Saturday, February 24th. Citigroup reiterated an “outperform” rating and set a $380.00 target price (up from $350.00) on shares of Biogen in a research report on Tuesday, January 16th. Mizuho set a $400.00 target price on shares of Biogen and gave the company a “buy” rating in a research report on Thursday, January 18th. Finally, Jefferies Group reiterated a “hold” rating on shares of Biogen in a research report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and twenty-one have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $366.49.

Shares of BIIB stock opened at $257.65 on Friday. Biogen Inc has a 12-month low of $244.28 and a 12-month high of $370.57. The stock has a market cap of $57,629.68, a P/E ratio of 11.81, a PEG ratio of 1.50 and a beta of 0.86. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. During the same period in the prior year, the business earned $5.04 earnings per share. The company’s revenue for the quarter was up 15.1% on a year-over-year basis. equities research analysts expect that Biogen Inc will post 24.82 EPS for the current fiscal year.

WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/ep-wealth-advisors-llc-takes-position-in-biogen-inc-biib.html.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply